Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imidafenacin - Kyorin Pharmaceutical/Ono Pharmaceutical

Drug Profile

Imidafenacin - Kyorin Pharmaceutical/Ono Pharmaceutical

Alternative Names: KRP 197; KRP-197OD; ONO 8025; ONO-8025OD; Staybla; Staybla OD Tablets; Uritos; Uritos OD Tablets

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Ajanta Pharma; Chong Kun Dang; Eisai Co Ltd; Kyorin Pharmaceutical; Ono Pharmaceutical
  • Class Imidazoles; Small molecules; Urologics
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder; Pollakisuria; Urinary incontinence
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 12 Apr 2021 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Japan (PO)
  • 01 Aug 2018 Imidafenacin licensed to Faes Farma in Latin America
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Overactive bladder(Adjunctive treatment, Combination therapy) in Japan (PO, Fast dissolve)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top